Psoriatic arthritis is treated with a combination of medications that calm the immune system, lifestyle changes that improve how well those medications work, and physical therapies that protect joint function. The goal isn’t just symptom relief. Modern treatment follows a “treat-to-target” strategy, meaning your rheumatologist will set a specific measurable target (like minimal disease activity) and adjust your treatment until you hit it. This approach produces better long-term outcomes than simply managing flares as they come.
First-Line Medication: Where Treatment Starts
Current guidelines from the American College of Rheumatology and the National Psoriasis Foundation recommend a biologic that blocks a protein called TNF-alpha as the preferred first treatment for active psoriatic arthritis. These biologics are favored over older oral medications because they tend to work faster and more effectively for both joint and skin symptoms. They’re given by injection, typically at home, on a schedule your doctor sets.
Older oral medications, sometimes called conventional DMARDs, are still used. Methotrexate is the most common. These drugs broadly suppress the immune system rather than targeting a specific pathway, which means they can help with inflammation but often don’t work as well for certain features of psoriatic arthritis like spine involvement or tendon pain. They’re sometimes prescribed alongside a biologic or used when biologics aren’t an option due to cost, insurance, or patient preference.
Newer Biologics Targeting IL-17 and IL-23
Beyond TNF blockers, a newer generation of biologics targets other immune proteins involved in psoriatic arthritis. IL-17 inhibitors (secukinumab, ixekizumab, bimekizumab, brodalumab) and IL-23 inhibitors (guselkumab, risankizumab, tildrakizumab) have expanded the options significantly, especially for people who don’t respond to TNF blockers or who have extensive skin disease alongside joint symptoms.
A large network analysis comparing these drugs found that IL-17 inhibitors, particularly bimekizumab, secukinumab, and ixekizumab, showed the strongest results for joint improvement. Bimekizumab ranked highest for achieving a 20% and 50% improvement in joint symptoms, while ixekizumab ranked highest for reaching minimal disease activity, a composite measure that captures improvement across joints, skin, pain, and function simultaneously.
Bimekizumab is the newest addition to this class, approved by the FDA in September 2024. It’s the first treatment that blocks both IL-17A and IL-17F, two closely related proteins that drive inflammation. It’s given as a subcutaneous injection every four weeks. In clinical trials, it did carry a higher rate of nasopharyngitis (common cold-like symptoms) compared to placebo, but serious side effects were not significantly different from other biologics in this class.
JAK Inhibitors: Oral Alternatives to Biologics
JAK inhibitors are oral pills that block specific signaling pathways inside immune cells. Several have been studied or approved for psoriatic arthritis, including tofacitinib and upadacitinib. For many patients, the appeal is simple: they’re pills, not injections.
However, these medications come with additional safety considerations. A large surveillance study in patients over 50 with at least one cardiovascular risk factor raised concerns about heart-related events, blood clots, and certain cancers. Because of this, JAK inhibitors are generally reserved for patients who haven’t responded to or can’t tolerate other treatments. If your doctor recommends one, expect a conversation about your personal risk factors and more frequent blood work to monitor for problems.
Why Weight Loss Matters More Than You Think
Losing weight doesn’t just reduce stress on your joints. It dramatically changes how well your medications work. A study published in the Annals of the Rheumatic Diseases tracked patients starting biologic therapy and found that those who lost at least 5% of their body weight were over four times more likely to reach minimal disease activity compared to those who lost less. The relationship was dose-dependent: among patients who lost less than 5% of their weight, only 23% reached the target. That jumped to 45% for those who lost 5 to 10%, and nearly 60% for those who lost more than 10%.
These are striking numbers. For a 200-pound person, 5% is just 10 pounds. That relatively modest change nearly doubled the odds of reaching a meaningful treatment goal. If you’re carrying extra weight and starting a new medication, pairing it with even a gradual weight loss plan can make a real difference in whether that medication gets you where you need to be.
Exercise and Physical Therapy
Guidelines specifically recommend that people with active psoriatic arthritis use exercise, physical therapy, occupational therapy, or a combination of these alongside their medications. Low-impact options like swimming, tai chi, and yoga are preferred because they build strength and flexibility without adding stress to inflamed joints. That said, if you prefer running or other high-impact activities and your joints can handle it, the guidelines don’t prohibit it.
The practical benefits go beyond fitness. Regular movement reduces the morning stiffness that many people with psoriatic arthritis describe as one of their most frustrating symptoms. Occupational therapy can help you find ways to protect your hands and wrists during daily tasks, which matters because the small joints of the fingers are commonly affected. Massage therapy and acupuncture are also conditionally recommended as complementary options.
Light Therapy for Skin Symptoms
If your psoriatic arthritis comes with significant skin plaques, narrowband UVB phototherapy is considered the gold standard light-based treatment. When UVB light hits the skin, it reduces the specific immune signals that drive psoriasis, promotes regulatory immune cells that suppress autoimmune reactions, and stimulates vitamin D production, which helps slow the rapid skin cell turnover that creates plaques.
Phototherapy is done in a doctor’s office, typically two to three times a week. For small, stubborn patches, especially on the scalp, an excimer laser delivers a concentrated beam of UVB light that penetrates deeper into the skin. Light therapy treats the skin component of the disease but doesn’t reach the joints, so it’s used alongside systemic medications rather than as a standalone treatment.
What “Treat to Target” Looks Like in Practice
Modern psoriatic arthritis management sets a clear finish line: minimal disease activity, or MDA. This means meeting at least five out of seven clinical criteria that together capture how your joints, skin, pain levels, and physical function are doing. A stricter goal, very low disease activity, requires meeting all seven. Your rheumatologist will assess these benchmarks at regular follow-up visits, typically every three to six months.
If your current treatment isn’t getting you to MDA within a reasonable window (usually around 12 to 24 weeks for biologics), your doctor will adjust. That might mean switching biologic classes, adding a conventional DMARD, or addressing factors that blunt medication effectiveness, like excess weight. The key principle is that treatment shouldn’t be static. If you’re still struggling with pain, swelling, or stiffness, that’s a signal to push for a change rather than accept it as your baseline.